

## **VALUE AND SCENARIOS OF DIFFERENT TEST**

### **Authors:**

**Salvador Morales-Conde,**

**Federico Garcia (Microbiologist)**

**Eduardo Targarona,**

**Nicolas Demartines,**

**Mario Alvarez**

**And the collaborative group “Corona Virus Global Surgical Collaborative (CVGSC)” and “Surgery-AEC-COVID”**

**“Surgery-AEC-COVID”:** Salvador Morales-Conde, Estíbaliz Álvarez Peña, Mario Álvarez Gallego, José Manuel Aranda Narváez, Josep María Badia, José María Balibrea, Sandra García Botella, Xavier Guirao, Eloy Espín Basany, Esteban Martín Antona, Elena Martín Pérez, Sagrario Martínez Cortijo, Isabel Pascual Miguelañez, Lola Pérez Díaz, José Luis Ramos Rodríguez, Inés Rubio Pérez, Raquel Sánchez Santos

## TEST FOR DIRECT DIAGNOSIS

<b>TYPE OF TEST</b>	<b>What does this test measure?</b>	<b>Sample origin</b>	<b>Testing timing</b>	<b>Meaning if positive</b>	<b>Meaning if negative</b>	<b>Sensitivity</b>	<b>False negative</b>	<b>Timing of test positivity* (approx.)</b>	<b>Timing of test negativity* (approx.)</b>	<b>Clinical significance</b>
<b>Test for Direct Diagnosis</b>										
<b>PCR</b>	<b>Viral RNA</b>	Swab from nasopharynx	Symptom onset and screening of asymptomatic	Patient is infected	Not infected or False –	High	Low (very dependent on correct sampling)	Before symptom onset	8 days after symptoms onset	If +, the patient is contagious
		Sputum	Symptom onset		or Disease is finished and no possibility to infect	High	Low	After symptom onset	From day 7 to day 22 after symptom onset	If +, the patient is contagious (less likely than in above scenario)
		Stool (not a commonly used diagnostic test)	Symptom onset		or infected but in a very early stage	High	Low	After symptom onset	From day 7 to day 22 after symptom onset	If +, the patient is contagious, although doubts (although it is not known very well but while it is demonstrated, it is necessary to be very cautious)
<b>Antigen**</b>	<b>Viral antigens</b>	Swab from nasopharynx	Not recommended due to low sensitivity	Patient is infected	Same as PCR	Low	High	Same as PCR	Same as PCR	Not yet recommended for COVID 19 acute phase
		Sputum	Not recommended	Patient is infected		-	-			

\* Subject to individual variations

\*\* Fast tests

**TEST FOR INDIRECT DIAGNOSIS OR SEROLOGY**

<b>TYPE OF TEST</b>	<b>What does this test measure?</b>	<b>Sample origin</b>	<b>Testing timing</b>	<b>Meaning if positive</b>	<b>Meaning if negative</b>	<b>Sensitivity</b>	<b>False negative</b>	<b>Timing of test positivity* (approx.)</b>	<b>Timing of test negativity* (approx.)</b>	<b>Clinical significance</b>
<b>Test Indirect diagnosis or Serology</b>										
<b>IgM**</b>	<b>IgM antibody</b>	Blood/Serum/Plasma	Any time	Active infection, being the first antibodies produced during the immune response	Not infected but does not exclude active infection	High (highest 10 days after onset of infection)	Moderate	5-7 days from infection (best results 8-14 days )	30 days from infection	<p>If positive without possibility of a test for PCR: Active infection and patient should be isolate and treat</p> <p>If positive after PCR becoming negative: assess individually</p> <p>They are important if symptomatic and PCR -</p>
<b>IgG**</b>	<b>IgG antibody</b>	Blood/Serum/	Any time	Antibodies produced in a late stage (past infection)	Early infection or Not infected	High (high after 10 days after infection)  60% at day 7 and 100% at day 14	Low	15-21 days from infection	Unknown	<p>If positive: Past infection (even in asymptomatic patients) but Small % of patients could have PCR + and possibility of infect contacts</p>

\* Subject to individual variations

\*\* Fast tests

## TEST INTERPRETATION

<b>PCR*</b>	<b>IgM</b>	<b>IgG</b>	<b>Fig 1</b>	<b>Stage of infection</b>	<b>Interpretation pitfalls*/**</b>	<b>Risk of infecting contacts</b>
-	-	-	1	<b>Negative (not infected)</b>	Risk of false negative in early stage of infection. (Watch out if contact with infected patient or symptomatic!!)	Low chance of infecting contacts. Infective, if PCR is false negative
+	-	-	2	<b>Window stage or Initial stage of the disease</b>	-	High chance of infecting contacts
+	+	-	3	<b>Early stage of the disease</b>	Warning: When performing only IgM testing: If only serological tests are performed, one can mistakenly assume past infection, and still be contagious	High chance of infecting contacts
+	+	+	4	<b>Active stage of the disease</b>	Warning: When performing only IgM: If only serological tests are performed, one can mistakenly assume past infection, and still be contagious	High chance of infecting contacts
+	-	+	5	<b>Final stage of the disease</b>	Warning: If only serological tests are performed, one can mistakenly assume past infection, and still be contagious	High chance of infecting contacts
-	+	-	6	<b>Initial stage of the disease with PCR false negative or last phase of the initial stage with low viral load</b>	Warning: Patient can be contagious if PCR is a False negative.  False positive of IgM	High chance of infecting contacts if PCR is false negative Moderate chance if true negative
-	-	+	7	<b>Past Infection</b>	Warning: Patient can be contagious if PCR is a false negative.	Low chance of infecting contacts
-	+	+	8	<b>Disease is evolving</b>	Warning: Patient can be contagious if PCR is a false negative.	Low chance of infecting contacts

\*Results from the test for antigens would be considered as the PCR, but only if the results of the test for antigen is positive since sensibility of this test is low

\*\*The risk of interpretation is also based on the correct sampling for PCR




Figure 1.- Different combinations of the results of the test

(1)(2)(3)(4)(5)(6)(7)

1. Wei WE, Li Z, Chiew CJ, Yong SE, Toh MP, Lee VJ. Presymptomatic Transmission of SARS-CoV-2 — Singapore, January 23–March 16, 2020. *MMWR Morb Mortal Wkly Rep* [Internet]. 2020 Apr 10 [cited 2020 Apr 15];69(14):411–5. Available from: [http://www.cdc.gov/mmwr/volumes/69/wr/mm6914e1.htm?s\\_cid=mm6914e1\\_w](http://www.cdc.gov/mmwr/volumes/69/wr/mm6914e1.htm?s_cid=mm6914e1_w)
2. Surveillance, rapid response teams, and case investigation [Internet]. [cited 2020 Apr 15]. Available from: <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/surveillance-and-case-definitions>
3. Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y, et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. *Clin Infect Dis* [Internet]. 2020 Mar 28; Available from: <https://doi.org/10.1093/cid/ciaa344>
4. Balibrea JM, Badia JM, Rubio Pérez I, Martín Antona E, Álvarez Peña E, García Botella S, et al. Surgical Management of Patients With COVID-19 Infection. Recommendations of the Spanish Association of Surgeons. *Cir Esp*. 2020;
5. Advice on the use of point-of-care immunodiagnostic tests for COVID-19 [Internet]. [cited 2020 Apr 15]. Available from: <https://www.who.int/news-room/commentaries/detail/advice-on-the-use-of-point-of-care-immunodiagnostic-tests-for-covid-19>
6. Coronavirus disease 2019 (COVID-19): Epidemiology, virology, clinical features, diagnosis, and prevention - UpToDate [Internet]. [cited 2020 Apr 15]. Available from: <https://www-uptodate-com.m-hulp.a17.csinet.es/contents/coronavirus-disease-2019-covid-19-epidemiology-virology-clinical-features-diagnosis-and-prevention#H2325386707>
7. (No Title) [Internet]. [cited 2020 Apr 15]. Available from: [https://seimc.org/contenidos/documentoscientificos/recomendaciones/seimc-rc-2020-Posicionamiento\\_SEIMC\\_diagnostico\\_microbiologico\\_COVID19.pdf](https://seimc.org/contenidos/documentoscientificos/recomendaciones/seimc-rc-2020-Posicionamiento_SEIMC_diagnostico_microbiologico_COVID19.pdf)